comparison of us and european guidelines
DESCRIPTION
Comparison of US and European Guidelines. Oral Antiplatelet Therapy in Primary PCI/STEMI. GP IIb/IIIa Inhibitors in Primary PCI/STEMI. EUROMAX Bleeding Outcomes at 30 d. HORIZONS-AMI Bleeding Outcomes at 30 d in a Primary PCI Population. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/1.jpg)
![Page 2: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/2.jpg)
![Page 3: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/3.jpg)
![Page 4: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/4.jpg)
Comparison of US and European Guidelines
![Page 5: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/5.jpg)
Oral Antiplatelet Therapy in Primary PCI/STEMI
![Page 6: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/6.jpg)
![Page 7: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/7.jpg)
GP IIb/IIIa Inhibitors in Primary PCI/STEMI
![Page 8: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/8.jpg)
EUROMAXBleeding Outcomes at 30 d
![Page 9: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/9.jpg)
HORIZONS-AMIBleeding Outcomes at 30 d in a Primary PCI
Population
![Page 10: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/10.jpg)
CHAMPION PHOENIX Primary Efficacy Outcomes at 48 h, MITT
![Page 11: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/11.jpg)
Anticoagulation in Primary PCI/STEMI
![Page 12: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/12.jpg)
FUTURA/OASIS 8
![Page 13: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/13.jpg)
Oral Antiplatelet Therapy in Non-ST Elevation ACS
![Page 14: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/14.jpg)
CHARISMABleeding End Points by Baseline Daily Aspirin
Dose
![Page 15: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/15.jpg)
CURRENTEfficacy and Bleeding by Aspirin Dose
![Page 16: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/16.jpg)
EARLY-ACSBleeding Outcomes at 30 days
![Page 17: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/17.jpg)
GP IIb/IIIa Inhibitors in Primary PCI/Non-ST-segment Elevation ACS
![Page 18: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/18.jpg)
PLATO SubanalysisEfficacy and Safety End Points
![Page 19: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/19.jpg)
Anticoagulation in Non-ST-segment Elevation ACS
![Page 20: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/20.jpg)
OASIS 5 -- Cumulative Risk of Death, MI, or Refractory Ischemia
![Page 21: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/21.jpg)
The Future for ACS Management?
![Page 22: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/22.jpg)
Abbreviations
![Page 23: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/23.jpg)
Abbreviations (cont)
![Page 24: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/24.jpg)
References
![Page 25: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/25.jpg)
References (cont)
![Page 26: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/26.jpg)
References (cont)
![Page 27: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/27.jpg)
References (cont)
![Page 28: Comparison of US and European Guidelines](https://reader036.vdocuments.mx/reader036/viewer/2022062500/56815ab2550346895dc86109/html5/thumbnails/28.jpg)
References (cont)